Citations

Clear

448 citation(s) found for "Ja, Fields".

Novel GRN mutation presenting as an aphasic dementia and evolving into corticobasal syndrome
Finch, NiCole A., Gavrilova, Ralitza H. , Fields, Julie A. , Lowe, Val J. , Petersen, Ronald C. , Jack, Clifford R. , Dheel, Christina, Gearhart, Debra, Rademakers, Rosa , Dheel, Christina M, Gearhart, Debra J, Jack, Clifford R , Botha, Hugo , Machulda, Mary M. , Knopman, David S. , Boeve, Bradley F.

Mayo Clinic

Neurology Genetics | December 13, 2017 | Volume: 3 | Issue: 6 | Pages: No page available

10.1212/nxg.0000000000000201 | PMID 29264393 Get It

[P1–483]: LONGITUDINAL PERFORMANCE ON THE KING DEVICK TEST IN PATIENTS WITH REM SLEEP BEHAVIOR DISORDER +/‐ MILD COGNITIVE IMPAIRMENT
Boeve, Angelica, Timm, Paul, McCord, Siri V., Sandness, David J., Jung, Youngsin, Fields, Julie A. , Silber, Michael H. , McCarter, Stuart J. , Botha, Hugo , Ferman, Tanis J. , Louis, Erik K. St. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | October 20, 2017 | Volume: 13 | Issue: 7S_Part_9 | Pages: No page available

10.1016/j.jalz.2017.06.499 Get It

Computer versus Compensatory Calendar Training in Individuals with Mild Cognitive Impairment: Functional Impact in a Pilot Study
Chandler, Melanie , Duncan, Noah, Hanna, Sherrie , Cuc, Andrea , Fields, Julie A. , Hoffman‐Snyder, Charlene , Lunde, Angela , Chandler, Melanie J, Locke, Dona E.C. , Hanna, Sherrie M, Cuc, Andrea V , Hoffman Snyder, Charlene R, Lunde, Angela M, Smith, Glenn E.

Mayo Clinic

Brain Sciences | September 6, 2017 | Volume: 7 | Issue: 9 | Pages: 112

10.3390/brainsci7090112 | PMID 28878146 Get It

This pilot study examined the functional impact of computerized versus compensatory calendar training in cognitive rehabilitation participants with mild cognitive impairment (MCI). Fifty-seven participants with amnestic MCI completed randomly assigned calendar or computer training. A standard care control group was used for comparison. Measures of adherence, memory-based activities of daily living (mADLs), and self-efficacy were completed. The calendar training group demonstrated significant improvement in mADLs compared to controls, while the computer training group did not. Calendar training may be more effective in improving mADLs than computerized intervention. However, this study highlights how behavioral trials with fewer than 30–50 participants per arm are likely underpowered, resulting in seemingly null findings.
The Evolving Role of Tumor Treating Fields in Managing Glioblastoma
Burri, Stuart H., Gondi, Vinai , Brown, Paul D. , Mehta, Minesh P.

Mayo Clinic

American Journal of Clinical Oncology | August 23, 2017 | Volume: 41 | Issue: 2 | Pages: 191-196

10.1097/coc.0000000000000395 | PMID 28832384 Get It

Glioblastoma (GBM) is a devastating brain tumor with poor prognosis despite advances in surgery, radiation, and chemotherapy. Survival of patients with glioblastoma remains poor, with only 1 in 4 patients alive at 2 years, and a 5-year survival rate of about 5%. Recurrence is nearly universal and, after recurrence, prognosis is poor with very short progression-free survival and overall survival (OS). Various salvage chemotherapy strategies have been applied with limited success. Tumor Treating Fields (TTFields) are a novel treatment modality approved for treatment of either newly diagnosed or recurrent GBM. TTFields therapy involves a medical device and transducer arrays to provide targeted delivery of low intensity, intermediate frequency, alternating electric fields to produce antimitotic effects selective for rapidly dividing tumor cells with limited toxicity. In the phase 3 EF-14 trial, TTFields plus temozolomide provided significantly longer progression-free survival and OS compared with temozolomide alone in patients with newly diagnosed GBM after initial chemoradiotherapy. The addition of TTFields to standard therapy improved median OS from 15.6 to 20.5 months (P=0.04). In the phase 3 EF-11 trial, for recurrent GBM, TTFields provided comparable efficacy as investigator’s choice systemic therapy, with improved patient-reported quality of life and a lower incidence of serious adverse events. Primary toxicity associated with TTFields is skin irritation generally managed with array relocation and topical treatments including antibiotics and steroids. TTFields therapy has demonstrated proven efficacy in management of GBM, including improvement in OS for patients with newly diagnosed GBM, and is under current investigation in other brain and extracranial tumors.
Oncogenic Ect2 signaling regulates rRNA synthesis in NSCLC
Justilien, Verline , Lewis, Kayla C., Murray, Nicole R., Fields, Alan P.

Mayo Clinic

Small GTPases | June 28, 2017 | Volume: 10 | Issue: 5 | Pages: 388-394

10.1080/21541248.2017.1335274 | PMID 28657426 Get It